Physician profile
Evan Scott Collier
NPI 1386779510
$3,060.04
in general payments reported to CMS, 2019-2025
26 companies · $448 in 2025
The $448 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $560 · 2020: $13.13 · 2021: $109 · 2022: $586 · 2023: $699 · 2024: $646 · 2025: $448.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,792.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,792.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $669.51 | 2019-2025 | Belbuca |
| Scilex Pharmaceuticals INC. | $484.02 | 2022-2024 | Ztlido |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $360.91 | 2020-2025 | Relistor |
| Abbott Laboratories | $242.79 | 2019-2024 | Proclaim, Eterna |
| Almatica Pharma LLC | $208.42 | 2023 | Gralise |
| Si-Bone, INC. | $129.99 | 2022 | |
| Nalu Medical, INC. | $101.75 | 2023-2024 | Nalu Neurostimulation System |
| Curonix LLC | $96.67 | 2024-2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Indivior INC. | $90.24 | 2024-2025 | Sublocade |
| Biodelivery Sciences International, INC. | $66.29 | 2019 | |
| Fidia Pharma USA INC. | $63.42 | 2022-2023 | Hymovis, Triluron |
| Boston Scientific Corporation | $59.19 | 2023-2024 | Wavewriter Alpha Prime 16 |
| Nevro Corp. | $58.78 | 2022-2023 | Senza |
| Electronic Waveform Lab, INC. | $57.90 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $57.05 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $55.03 | 2019-2023 | |
| Vertex Pharmaceuticals Incorporated | $45.62 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $42.33 | 2019 | |
| Globus Medical, INC. | $33.77 | 2025 | Senza |
| Abbvie INC. | $28.37 | 2022 | |
| Redhill Biopharma INC. | $25.84 | 2021-2023 | |
| Kaleo, INC. | $22.16 | 2019 | |
| Lilly USA, LLC | $18.76 | 2019 | |
| Amgen INC. | $16.93 | 2019 | |
| Shionogi INC | $12.20 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $12.10 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Evan Collier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.